Moderna's Trading Volume Drops to $323 Million Amid Legal Battles and Market Downturn

On April 1, 2025, Moderna's trading volume reached $323 million, marking a 43.52% decrease from the previous day. The company's stock price fell by 4.20%, extending its losing streak to three days, with a cumulative decline of 15.44% over the past three days.

Moderna has recently faced legal challenges from Genevant Sciences and Arbutus Biopharma Corporation, which have filed lawsuits alleging patent infringements related to the company's lipid nanoparticle technology. These legal disputes have impacted investor sentiment and contributed to the decline in Moderna's share price.

In addition to the legal issues, broader market trends have also affected Moderna's stock performance. The company's exclusion from the NASDAQ-100 Index in December 2024 further highlighted the declining investor confidence. Despite efforts at diversification, such as Health Canada's approval of the mRESVIA vaccine for adults, Moderna continues to face challenges, including inventory write-downs and a net loss of $3.6 billion in 2024.

Over the past year, Moderna has underperformed both the U.S. market and the Biotech industry. The U.S. market posted a 6.1% increase, while the Biotech industry experienced an 11.9% decline. These factors, combined with the ongoing legal battles and financial performance, have weighed on Moderna's stock price.